Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and Effect.

Simple Summary: This study explores the efficacy and safety of alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) regimens in patients with metastatic pancreatic cancer (MPC). The approach aims to reduce toxicity, slow resistant cancer biology, and facilitate the in...

Descripción completa

Detalles Bibliográficos

Publicado en:	Cancers Vol. 15; no. 23; pp. 5588 - 5598
Autores principales:	Schroeder, Brett A., Mandelson, Margaret T., Picozzi, Vincent J.
Formato:	research tables/charts Journal Article
Publicado:	MDPI Dec2023
Acceso en línea:	Ver este registro en EBSCOhost